LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

Home・Aktien・Krystal Biotech Inc

Krystal Biotech Inc

Geschlossen

BrancheGesundheitswesen

275.14 1.85

Buy Sell

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

270.6

Max

279.77

Schlüsselkennzahlen
By Trading Economics
Einkommen	41M 79M
Verkäufe	1.8M 98M
KGV Branchendurchschnitt	40.81 121.746
Gewinnspanne	81.15
Angestellte	275
EBITDA	10M 50M

Empfehlungen
By TipRanks
Empfehlungen	Starkes Kaufsignal
12-Monats-Prognose	+16.01% upside

Dividenden
By Dow Jones
Nächstes Ergebnis	17. Feb. 2026

Marktstatistiken
By TradingEconomics
Marktkapitalisierung	2.4B 7.9B
Vorheriger Eröffnungskurs	273.29
Vorheriger Schlusskurs	275.14

Technischer Score

By Trading Central

Vertrauen

Very Strong Bearish Evidence

133.221 / 169.73 Unterstützung & Widerstand

Krystal Biotech Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

13. Feb. 2026, 16:32 UTC

Ergebnisse

Enbridge, TC Energy Investing in Opportunities to Tap Rising Energy Demand, Boom in Data Centers -- Update

13. Feb. 2026, 21:57 UTC

Ergebnisse

Stocks Rise on Softer Inflation Data, but AI Jitters Trigger Worst Week Since November -- WSJ

13. Feb. 2026, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

13. Feb. 2026, 21:20 UTC

Ergebnisse

Applied Materials, Rivian, Moderna, Arista, Fastly, Coinbase, Robinhood, DraftKings, and More Stock Market Movers -- Barrons.com

13. Feb. 2026, 21:05 UTC

Akquisitionen, Fusionen, Übernahmen

Constellation Software: Lumine Group Completes Acquisition of Synchronoss Technologies >CSU.T SNCR

13. Feb. 2026, 20:45 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

13. Feb. 2026, 20:45 UTC

Market Talk

Dollar Pares Down Early Losses -- Market Talk

13. Feb. 2026, 20:39 UTC

Market Talk

Potential for Mild Winter Ahead Sinks Natural Gas for Week -- Market Talk

13. Feb. 2026, 20:28 UTC

Market Talk

Oil Settles Week Lower -- Market Talk

13. Feb. 2026, 19:51 UTC

Ergebnisse

These Stocks Are Today's Movers: Applied Materials, Rivian, Moderna, Arista, Fastly, Coinbase, Robinhood, DraftKings, and More -- Barrons.com

13. Feb. 2026, 19:32 UTC

Market Talk

Gold and Silver Climb to Finish Week In Positive Territory -- Market Talk

13. Feb. 2026, 19:32 UTC

Market Talk

Gold and Silver Climb to Finish Week In Positive Territory -- Market Talk

13. Feb. 2026, 19:29 UTC

Ergebnisse

Big Tech's Spending Spree Could Limit Buybacks and Dividends -- Barrons.com

13. Feb. 2026, 18:18 UTC

Akquisitionen, Fusionen, Übernahmen

Exxon, Walmart and 9 Other Stocks That Are Soaring Because Cash Is King Again -- Barrons.com

13. Feb. 2026, 17:52 UTC

Ergebnisse

Pinterest's Earnings Give More Proof of Meta Platform's Dominance -- Barrons.com

13. Feb. 2026, 17:16 UTC

Ergebnisse

These Stocks Are Today's Movers: Applied Materials, Rivian, Moderna, Arista, Fastly, Coinbase, Robinhood, DraftKings, and More -- Barrons.com

13. Feb. 2026, 17:10 UTC

Akquisitionen, Fusionen, Übernahmen

Vibe-Coding in Gas Town? A Guide to the Software Selloff With 4 Sexy Stock Picks. -- Barrons.com

13. Feb. 2026, 16:59 UTC

Ergebnisse

AppLovin Stock Stabilizes After Selloff. Its Biggest Critic Waves the White Flag. -- Barrons.com

13. Feb. 2026, 16:39 UTC

Akquisitionen, Fusionen, Übernahmen

Berkshire Might Have Sold More Apple, Bank of America Stock in Fourth Quarter -- Barrons.com

13. Feb. 2026, 16:11 UTC

Ergebnisse

Nvidia Stock Wobbles. The Focus Is Turning to Earnings. -- Barrons.com

13. Feb. 2026, 16:07 UTC

Market Talk

Hungarian Forint Could Rise Further -- Market Talk

13. Feb. 2026, 15:54 UTC

Ergebnisse

Detroit Automakers Take $50 Billion Hit as EV Bubble Bursts -- WSJ

13. Feb. 2026, 15:26 UTC

Market Talk

Indian Imports of Saudi Crude Hit Highest Since 2022 -- Market Talk

13. Feb. 2026, 15:01 UTC

Ergebnisse

These Stocks Are Today's Movers: Applied Materials, Rivian, Moderna, Steel Dynamics, Coinbase, DraftKings, Tri Pointe Homes, and More -- Barrons.com

13. Feb. 2026, 15:00 UTC

Ergebnisse

Expedia Falls, but Airbnb Rises. Why Online Travel Stocks Face a Tough Year. -- Barrons.com

13. Feb. 2026, 14:50 UTC

Market Talk

Oil Moves Lower As Market Weighs Geopolitical Risk -- Market Talk

13. Feb. 2026, 14:44 UTC

Ergebnisse

Arista Networks Stock Climbs. Why It Is Outshining Cisco. -- Barrons.com

13. Feb. 2026, 14:22 UTC

Market Talk

Ergebnisse

Global Energy Roundup: Market Talk

13. Feb. 2026, 14:21 UTC

Market Talk

Ergebnisse

TC Energy's Broadly Anticipated Results Expected To Have Neutral Response -- Market Talk

13. Feb. 2026, 14:13 UTC

Market Talk

U.S. Natural Gas Futures Move Lower -- Market Talk

Peer-Vergleich

Kursveränderung

Krystal Biotech Inc Prognose

Kursziel

By TipRanks

16.01% Vorteil

12-Monats-Prognose

Durchschnitt 316.29 USD 16.01%

Hoch 338 USD

Tief 295 USD

Basierend auf 8 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Krystal Biotech Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Starkes Kaufsignal

8 ratings

Buy

Halten

Sell

Basierend auf 8 Analysten, die in den letzten 3 Monaten Aktienbewertungen für Krystal Biotech Inc – Dist abgegeben haben.

Technischer Score

By Trading Central

133.221 / 169.73Unterstützung & Widerstand

Recent bearish events outweigh bullish events.

There is one bearish event.

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

Über Krystal Biotech Inc

Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). The company also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cystic fibrosis; KB707 that is in Phase 1 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.